Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10145 (
IL-8
)
23,849
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Inhaled corticosteroids (ICS) are widely used for the treatment of
COPD
despite of controversial statements concerning their efficacy. The use of N-acetylcysteine (NAC), a mucolytic drug with antioxidant properties, is less clear, but it may counteract the oxidant-antioxidant imbalance in
COPD
. The aim of this study was to evaluate whether treatment of
COPD
patients with ICS or NAC is able to improve inflammatory indices and to enhance lung function. ICS treatment enhanced protective markers for oxidative stress such as glutathione peroxidase (GPx) (51.2 +/-5.8 vs. 62.2 +/-8.6 U/g Hb, P<0.02) and trolox-equivalent antioxidant capacity (TEAC) (1.44 +/-0.05 vs. 1.52 +/-0.06 mM, P<0.05). NAC decreased sputum eosinophil cationic protein (318 +/-73 vs. 163 +/-30 ng/ml, P<0.01) and sputum
IL-8
(429 +/-80 vs. 347 +/-70 ng/ml, P<0.05). The increased antioxidant capacity prevented an up-regulation of adhesion molecules, since the levels of intracellular adhesion molecule 1 (ICAM-1) correlated negatively with GPx (P<0.0001) and TEAC (P<0.0001). On the other hand, expression of adhesion molecules was promoted by inflammation, reflected by a positive correlation between the levels of
IL-8
and ICAM-1 (P<0.0001). The effects of treatment on lung function were only reflected in the FEV(1) values. The absolute value of FEV(1), both before and after salbutamol inhalation, increased from 1690 +/-98 to 1764 +/-110 ml, and 1818 +/-106 to 1906 +/-116 ml, respectively, after ICS (P<0.05) . Ten weeks after treatment, FEV(1) values dropped to 1716 +/-120 ml post-salbutamol (P<0.05). When followed by treatment with NAC, these values decreased even further to 1666 +/-84 ml. These results suggest that ICS improved lung function in
COPD
patients with moderate airflow obstruction, beside a minor improvement in the oxidant-antioxidant imbalance leading to a lesser expression of ICAM-1. Treatment with NAC decreased some inflammatory parameters and had indirectly an inhibitory effect on the expression of adhesion molecules.
...
PMID:New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. 1620 87
It is unclear how chronic expectoration influences airway inflammation in patients with chronic lung disease. The aim of this study was to investigate factors influencing inflammation in induced sputum samples, including, in particular, chronic sputum production. Myeloperoxidase, interleukin-8, leukotriene B4 (LTB4), neutrophil elastase, secretory leukoprotease inhibitor (SLPI) and protein leakage were compared in induced sputum samples from 48 patients (36 with chronic expectoration) with
COPD
(with and without alpha-1-antitrypsin deficiency; AATD), 9 individuals with AATD but without lung disease and 14 healthy controls. There were no differences in inflammation in induced sputum samples from healthy control subjects and from AATD deficient patients with normal lung function but without chronic expectoration (P>0.05). Inflammation in induced sputum from AATD patients with airflow obstruction and chronic sputum expectoration was significantly greater than for similar patients who did not expectorate:
Interleukin-8
(P<0.01), elastase activity (P=0.01), and protein leakage (P<0.01). The presence of spontaneous sputum expectoration in AATD patients with airflow obstruction was associated with increased neutrophilic airway inflammation in induced sputum samples. The presence of chronic expectoration in some patients will clearly complicate interpretation of studies employing sputum induction where this feature has not been identified.
...
PMID:Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency. 1625 94
Moraxella catarrhalis is a major cause of infectious exacerbations of chronic obstructive lung disease (
COPD
) and may also contribute to the pathogenesis of
COPD
. Little is known about M. catarrhalis-bronchial epithelium interaction. We investigated activation of M. catarrhalis infected bronchial epithelial cells and characterized the signal transduction pathways. Moreover, we tested the hypothesis that the M. catarrhalis-induced cytokine expression is regulated by acetylation of histone residues and controlled by histone deacetylase activity (HDAC). We demonstrated that M. catarrhalis induced a strong time- and dose-dependent inflammatory response in the bronchial epithelial cell line (BEAS-2B), characterized by the release of
IL-8
and GM-CSF. For this cytokine liberation activation of the ERK and p38 mitogen-activated protein (MAP) kinases and transcription factor NF-kappaB was required. Furthermore, M. catarrhalis-infected bronchial epithelial cells showed an enhanced acetylation of histone H3 and H4 globally and at the promoter of the il8 gene. Preventing histone deacetylation by the histone deacetylase inhibitor trichostatin A augmented the M. catarrhalis-induced
IL-8
response. After exposure to M. catarrhalis, we found a decrease in global histone deacetylase expression and activity. Our findings suggest that M. catarrhalis-induced activation of il8 gene transcription was caused by interference with epigenetic mechanisms regulating il8 gene accessibility. Our findings provide insight into important molecular and cellular mechanisms of M. catarrhalis-induced activation of human bronchial epithelium.
...
PMID:Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. 1639 88
Chronic obstructive pulmonary disease [
COPD
] is characterised by airflow limitation of peripheral airways that is not fully reversible and progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. There is also intense airway wall remodelling and evidence of systemic inflammation. Increased interleukin [IL]-6, IL-1beta, tumor necrosis factor-alpha [TNF-alpha], GRO-alpha, MCP-1 and
IL-8
levels are measured in sputum, with further increases during exacerbations. The bronchiolar epithelium over-expresses MCP-1, MIP-1alpha and
IL-8
.
IL-8
can account for sputum neutrophil chemotactic activity. TNFalpha and IL-1beta stimulate macrophages to produce matrix metalloproteinase-9 [MMP-9], and bronchial epithelial cells to produce extracellular matrix glycoproteins. Increased expression of transforming growth factor-beta [TGFbeta) and epidermal growth factor [EGF] occurs in the epithelium and submucosal cells; gene array studies reveal an excess of TGFbeta1, CTGF and PDGFRA in
COPD
. TGFbeta and EGF activate proliferation of fibroblasts, while activation of the EGF receptor leads to mucin gene expression. Anti-cytokine therapy could be in the form of soluble receptors or by neutralising antibodies, small compounds blocking cytokine receptors or incomplete and non-activating cytokines, inhibitors of protein activation and inhibitors of signal transduction and transcription such as via inhibition of mitogen-activated protein kinases [MAPK] and of transcription factor, nuclear factor kappaB. Anti-
IL-8
therapy has been tried with little effect on
COPD
, and current trials are on-going with TNF-alpha inhibitors. Other treatments such as phosphodiesterase 4 inhibitors have anti-cytokine effects that may underlie their beneficial effects in
COPD
.
...
PMID:Cytokines as targets in chronic obstructive pulmonary disease. 1678 67
Moraxella catarrhalis is an important pathogen in patients with chronic obstructive lung disease (
COPD
). While M. catarrhalis has been categorized as an extracellular bacterium so far, the potential to invade human respiratory epithelium has not yet been explored. Our results obtained by electron and confocal microscopy demonstrated a considerable potential of M. catarrhalis to invade bronchial epithelial (BEAS-2B) cells, type II pneumocytes (A549) and primary small airway epithelial cells (SAEC). Moraxella invasion was dependent on cellular microfilament as well as on bacterial viability, and characterized by macropinocytosis leading to the formation of lamellipodia and engulfment of the invading organism into macropinosomes, thus indicating a trigger-like uptake mechanism. In addition, the cells examined expressed TLR2 as well as NOD1, a recently found cytosolic protein implicated in the intracellular recognition of bacterial cell wall components. Importantly, inhibition of TLR2 or NOD1 expression by RNAi significantly reduced the M. catarrhalis-induced
IL-8
secretion. The role of TLR2 and NOD1 was further confirmed by overexpression assays in HEK293 cells. Overall, M. catarrhalis may employ lung epithelial cell invasion to colonize and to infect the respiratory tract, nonetheless, the bacteria are recognized by cell surface TLR2 and the intracellular surveillance molecule NOD1.
...
PMID:Moraxella catarrhalis is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly NOD1-dependent inflammatory immune response. 1705 39
Inhaled corticosteroids have a high level of topical anti-inflammatory activity. However, in patients with
COPD
these drugs have been reported to exert limited effects. A reduction in histone deacetylase (HDAC) activity is suggested to prevent the anti-inflammatory action of corticosteroids. Cigarette smoke is known to reduce HDAC expression. The aim of this study is to compare the outcome of corticosteroid therapy in both smoking and non-smoking
COPD
patients. Twenty-three smoking patients and 18 ex-smoking patients with
COPD
were treated with inhaled corticosteroids for a period of 2 months. Blood and induced sputum samples were collected before and after treatment. Values of FEV(1) %-predicted did not change upon the therapy, but there was a trend to improve in the ex-smokers (63.1 -> 64.8%-pred.), compared with a decrease in the smokers (63.3 -> 61.6%-pred.). The levels of the pro-inflammatory cytokine
IL-8
increased in the group of smokers from 379 +/-78 to 526 +/-118 ng/ml. Although not significant, a slight decrease from 382 +/-70 to 342 +/-62 ng/ml was observed in the group of ex-smokers. The neutrophil related elastase activity showed similar effects after steroid treatment, it went up from 36.4 +/-12.0 to 113.5 +/-9.7 nmol/l in smokers, and decreased from 346.2 +/-72.1 to 131.1 +/-6.5 nmol/l in ex-smokers with
COPD
. These results support the evidence that inhaled corticosteroids have no anti-inflammatory effects in
COPD
patients, but only when these patients are still smoking. Smoking cessation seems the best therapy for
COPD
patients.
...
PMID:Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. 1707 55
Besides their antibiotic effect, C14 and C15 macrolides exhibit immunomodulatory properties which can have therapeutic applications for chronic inflammation of the airways. In vitro studies have demonstrated the anti-inflammatory effects of macrolides: decreased productions of IL-6,
IL-8
, TNF alpha, chemotactism of polymorphonuclear neutrophils. Cell activity is modified with reduced production of elastase and oxidizing agents. These immunomodulator effects appear to result from an interaction with transcription factors which regulate the expression of cell gens. In addition, they lead to a modified bronchial mucosal secretion and have an action on the biofilm and the pseudomonas pilis. Their clinical activity has been demonstrated in panbronchiolitis and is in favor of use in cystic fibrosis. Use of macrolides should be carefully monitored in the event of bronchectasia,
COPD
, asthma, or chronic rhinosinusitis.
...
PMID:[Anti-inflammatory effects of macrolides: applications in lung disease]. 1707 45
The finding that alphal-antitrypsin (AAT) deficiency, PiZZ, a well-established genetic risk factor for
COPD
, is related to high levels of circulating AAT polymers, prompted us to measure serum levels of such polymers and selected markers of inflammation in age- and gender-matched patients with stable
COPD
and control subjects with and without severe AAT deficiency, and to assess their relationship with each other and with the genetic AAT-variant. We found that
COPD
individuals (n= 20), independent of AAT-variant, had significantly higher serum levels of AAT and its polymers, MMP-9, sICAM-1, VEGF and sE-selectin than controls (n=30). Subjects with PiZZ
COPD
(n= 10) showed significantly elevated serum levels of AAT-polymers, sE-selectin and sICAM-1, while patients with PiMM
COPD
(n= 10) showed higher levels of MMP-9, VEGF,
IL-8
and MCP-1 than controls. By using factor analysis we were able to split the analysed biomarkers into two independent components: the first containing MMP-9, MCP-1,
IL-8
and VEGF and the second-AAT and its polymers and sE-selectin. The result from the binomial logistic regression showed that 95.2 percent of the control individuals and 94.7 percent of the
COPD
patients can be correctly classified on the basis of the measured serum biomarkers. These observations highlight the importance of the finding sets of biomolecules, which could offer new strategies for the diagnosis of
COPD
and may have value for monitoring progression of
COPD
.
COPD
2004
PMID:Analysis of systemic biomarkers in COPD patients. 1713 83
A respiratory infection in childhood has been implicated in one of the risk factors for
COPD
. The hypothesis that latent adenoviral infection is involved in the pathogenesis of
COPD
have been studied for 15 years. A DNA virus, adenovirus(Ad), early gene 1A (ElA gene) was identified in lung tissue of
COPD
. The E1A gene expression enhances the soluble intercellular adhesion molecule (ICAM) 1 expression and the recruitment of inflammatory cells into airways of
COPD
lungs. In vitro experiments, E1A gene transfected cells exhibited the enhanced inflammatory response to tobacco smoke. The excess production of ICAM-1,
IL-8
, and TGF- beta by lung epithelial cells transfected with the Ad E1A gene. Respiratory infections in childhood including Ad infection may be an important risk factor for the pathogenesis of
COPD
.
...
PMID:[Childhood respiratory infection in the pathogenesis of COPD]. 1741 77
Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) ligands have the potential for use as anti-inflammatory agents in chronic airway diseases. We hypothesized that cigarette smoke (CS)-mediated pro-inflammatory cytokine release would be downregulated in the monocyte-macrophage cell line (MonoMac6) by synthetic and natural PPARgamma ligands. Surprisingly, treatment of MonoMac6 cells with the natural PPARgamma ligand 15-deoxy-Delta12,14-prostaglandin J2 led to increased cytokine (
IL-8
) release in response to either TNF-alpha or CS extract (CSE). However, exposure to rosiglitazone, a synthetic agonist, led to decreased TNF-alpha, but not CSE, mediated cytokine release. Cytokine release correlated with nuclear PPARgamma localization; CSE reduced the amount of activated PPARgamma located in the nucleus and formed aldehyde adducts as PPARgamma protein carbonyls. Furthermore, it was shown that PPARgamma interacts with the RelA/p65 subunit of NF-kappaB under TNF-alpha exposure conditions, but this interaction was disrupted by CS exposure, suggesting that CS blocks this important anti-inflammatory pathway involving PPARgamma. Thus, these new data show that activation of PPARgamma with natural or synthetic ligands have differential inhibitory effects on CS-mediated pro-inflammatory mediator release. These data have implications in designing therapies for treatment of
COPD
and pulmonary fibrosis.
...
PMID:Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, PPARgamma agonists, differentially regulate cigarette smoke-mediated pro-inflammatory cytokine release in monocytes/macrophages. 1797 Jun 47
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>